Newsletter | June 10, 2021

06.10.21 -- Solving Drug Formulation Challenges For Pharmaceutical Development And Manufacturing

 
Oral Drug Delivery Solutions
Five Key Tips To Enhance The Solubility Of Your Oral Drug Products
 

How can pharma companies minimize project risk and development costs, select the right excipients, equipment, and process technologies to complement their API and dosage form, and enable higher drug loadings and improve stability? Explore key factors to help ensure the path to solubility enhancement is as seamless and as low risk as possible.

Enabling Enteric Protection And Rapid Release In The Upper Small Intestine
 

Enteric coatings have been utilized with oral drug products for more than 60 years to protect acid-sensitive APIs from gastric acids and prevent gastric irritation by aggressive APIs. However, for many complex drug products targeting the small intestine or ileocolonic region, enteric protection on its own is insufficient to maximize absorption and enhance bioavailability.

Five Key Functional Challenges Can Affect Oral Drug Products With An Immediate Release Profile, Ready-To-Use Excipients Can Now Solve Them All
 

The market for oral drug products with an immediate release profile continues to move toward the development of more complex dosage forms designed to address specific functional or application requirements. While each formulation is different, customers most commonly want solutions to some combination of these five key challenges.

Enhancing The Stability, Survival And Performance Of Microbiota-Targeted Therapies And Other Microbiome-Based Products
 

The development of microbiota-targeted therapies and microbiome-based products creates significant opportunities to improve human health and well-being. For many pharmaceutical and biotech companies, it can be important to develop oral dosage forms that can deliver specific formulations or application outcomes.

Parenteral Drug Delivery Solutions
Lipid Nanoparticles Are Having A Breakout Moment
 

Lipid nanoparticles (LNPs) are now increasingly recognized as a preferred formulation technology for specialized parenteral drug products. Significant opportunities exist for LNP-based formulations to create drug products for protein replacement therapy, preventative or curative vaccines, and for gene editing purposes.

Beyond mRNA Vaccines: Emerging Applications For Lipid Nanoparticle Delivery Technologies
 

The potential of lipid nanoparticle (LNP)-based drug delivery technologies was made clear when the first two COVID-19 mRNA vaccines were rapidly developed and authorized for emergency use. Beyond the use of liposomes for small molecule drugs to target systemic diseases and LNPs for vaccines, what other applications are now being explored?

Cell And Gene Therapies Require Highly Specialized Formulation And Manufacturing Capabilities
 

Recent improvements in our understanding of the human genome, together with advanced DNA editing and analytical tools, positions the cell and gene therapy market for explosive growth. However, these technologies have significant formulation development, cGMP manufacturing, and aseptic filling challenges.

Ocular Drug Delivery — Developing Polymeric Implants And Other Formulations For Precise Intravitreal Administration
 

The development of polymeric formulations, such as intra-ocular implants designed for the precise intravitreal delivery of drug products, represents one of the most promising, yet challenging, areas of pharmaceutical focus. Review key challenges and emerging opportunities for ocular drug delivery and some of the latest excipients and process options available today.